非标准剂量阿替普酶静脉溶栓治疗急性缺血性卒中

被引：10

作者：

丘红燕 ^{[1
]}

彭伟彬 ^{[2
]}

胡俊 ^{[1
]}

吴军 ^{[1
]}

机构：

[1] 北京大学深圳医院神经内科

[2] 广州医科大学

来源：

中风与神经疾病杂志 | 2017年 / 34卷 / 08期

关键词：

急性缺血性卒中; 静脉溶栓; 阿替普酶; 剂量;

D O I：

10.19845/j.cnki.zfysjjbzz.2017.08.014

中图分类号：

R743.3 [急性脑血管疾病（中风）];

学科分类号：

1002 ;

摘要：

目的比较分析非标准剂量与标准剂量阿替普酶静脉溶栓治疗急性缺血性卒中的有效性和安全性的差异。方法连续纳入北京大学深圳医院自2007年初-2015年底进行阿替普酶静脉溶栓治疗的急性缺血性卒中患者。根据阿替普酶使用剂量,分为非标准剂量组(0.521～0.833 mg/kg)和标准剂量组(0.9 mg/kg),比较分析两剂量组溶栓24 h后颅内出血率、死亡率及90 d mRS评分情况。结果溶栓前mRS评分均为0分,其中非标准剂量组48例(0.521～0.833 mg/kg,中位数为0.7245 mg/kg);标准剂量组51例(0.9 mg/kg)。两剂量组溶栓前NIHSS评分中位数均为13分,发病到溶栓时间的均值分别为200.75 min和197.53 min。校正基线变量差异后,两组症状性颅内出血率(8.33%vs 5.88%,P=0.727),死亡率(6.25%vs 9.8%,P=0.796),90 d患者生活自理比例(64.58%vs 64.71%,P=0.641)及获得良好预后比例(56.25%vs 49.02%,P=0.645)之间的差异均无统计学意义。结论非标准剂量阿替普酶静脉溶栓具有与标准剂量相同的有效性及安全性。对于中国人群,阿替普酶最佳剂量可能处于0.6～0.9 mg/kg之间。

引用

页码：725 / 728

页数：4

共 11 条

[1] 急性缺血性卒中不同剂量阿替普酶静脉溶栓疗效比较 [J].

廖晓凌 ;

王伊龙 ;

潘岳松 ;

王春娟 ;

赵性泉 ;

王春雪 ;

刘丽萍 ;

王拥军 .

中国卒中杂志, 2014, 9 (07) :551-556

[2]

Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association[J] . James F. Meschia,Cheryl Bushnell,Bernadette Boden-Albala,Lynne T. Braun,Dawn M. Bravata,Seemant Chaturvedi,Mark A. Creager,Robert H. Eckel,Mitchell S.V. Elkind,Myriam Fornage,Larry B. Goldstein,Steven M. Greenberg,Susanna E. Horvath,Costantino Iadecola,Edward C. Jauch,Wesley S. Moore,John A. Wilson. Stroke . 2014 (12)

[3]

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials[J] . Jonathan Emberson,Kennedy R Lees,Patrick Lyden,Lisa Blackwell,Gregory Albers,Erich Bluhmki,Thomas Brott,Geoff Cohen,Stephen Davis,Geoffrey Donnan,James Grotta,George Howard,Markku Kaste,Masatoshi Koga,Ruediger von Kummer,Maarten Lansberg,Richard I Lindley,Gordon Murray,Jean Marc Olivo

[4]

Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis[J] . Lancet Neurology . 2010 (2)

[5] Feasibility and Safety of Intravenous Thrombolysis in Multiethnic Asian Stroke Patients in Singapore [J].

Sharma, Vijay K. ;

Tsivgoulis, Georgios ;

Tan, June H. ;

Wong, Lily Y. H. ;

Ong, Benjamin K. C. ;

Chan, Bernard P. L. ;

Teoh, Hock L. .

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2010, 19 (06) :424-430

[6]

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials[J] . Kennedy R Lees,Erich Bluhmki,Rüdiger von Kummer,Thomas G Brott,Danilo Toni,James C Grotta,Gregory W Albers,Markku Kaste,John R Marler,Scott A Hamilton,Barbara C Tilley,Stephen M Davis,Geoffrey A Donnan,Werner Hacke. The Lancet . 2010 (9727)

[7]

Outcomes of Thrombolytic Therapy for Acute Ischemic Stroke in Chinese Patients: The Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study[J] . A-Ching Chao,Hung-Yi Hsu,Chih-Ping Chung,Chung-Hsiang Liu,Chih-Hung Chen,Michael Mu-Huo Teng,Giia-Sheun Peng,Wen-Yung Sheng,Han Hwa Hu. Stroke . 2010 (5)

[8]

Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study[J] . Nils Wahlgren,Niaz Ahmed,Antoni Dávalos,Gary A Ford,Martin Grond,Werner Hacke,Michael G Hennerici,Markku Kaste,Sonja Kuelkens,Vincent Larrue,Kennedy R Lees,Risto O Roine,Lauri Soinne,Danilo Toni,Geert Vanhooren. The Lancet . 2007 (9558)

[9]

Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset: Japan Alteplase Clinical Trial (J-ACT)[J] . Takenori Yamaguchi,Etsuro Mori,Kazuo Minematsu,Jyoji Nakagawara,Kazuo Hashi,Isamu Saito,Yukito Shinohara. Stroke . 2006 (7)

[10] INTRAVENOUS RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN ACUTE CAROTID-ARTERY TERRITORY STROKE [J].

MORI, E ;

YONEDA, Y ;

TABUCHI, M ;

YOSHIDA, T ;

OHKAWA, S ;

OHSUMI, Y ;

KITANO, K ;

TSUTSUMI, A ;

YAMADORI, A .

NEUROLOGY, 1992, 42 (05) :976-982

← 1 2 →